Therapeutic exercise in non-alcoholic fatty liver disease: current approaches and evidence-based effectiveness
https://doi.org/10.17749/2949-5873/rehabil.2025.58
Abstract
Advances in medical science and healthcare significantly reduce the risk of severe liver disease progression in patients with metabolic disorders. Currently, non-alcoholic fatty liver disease (NAFLD) represents a global challenge for hepatology and rehabilitation medicine, with therapeutic exercise serving as the most effective non-pharmacological method to achieve steatosis regression and improve the metabolic profile. This literature review provides a systematic effectiveness analysis of various physical activity regimens in the management of NAFLD patients, which encompasses prevention, treatment, and rehabilitation. Molecular and biomechanical mechanisms of exercise, modern techniques for prescribing aerobic and resistance loads, and clinical applications of therapeutic exercise are discussed. Special attention is paid to the evidence base from randomized controlled trials and meta-analyses.
About the Authors
E. A. Zolozova
Russian Medical Academy of Continuous Professional Education
Russian Federation
Russian Federation
Elena A. Zolozova, PhD, Assoc. Prof.
2/1 bldg 1 Barrikadnaya Str., Moscow 125993
Scopus Author ID: 6504313491
T. E. Bogacheva
Ivanovo State Medical University
Russian Federation
Russian Federation
Tatiana E. Bogacheva, PhD, Assoc. Prof.
8 Sheremetyevsky Ave., Ivanovo 153012
Scopus Author ID: 57188826213
V. I. Demidov
Ivanovo State Medical University
Russian Federation
Russian Federation
Vadim I. Demidov, PhD, Assoc. Prof.
8 Sheremetyevsky Ave., Ivanovo 153012
WoS ResearcherID: F-9158-2019
Scopus Author ID: 56806409700
References
1. Younossi Z.M., Koenig A.B., Abdelatif D., et al. Global epidemiology of nonalcoholic fatty liver disease – meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016; 64 (1): 73–84. https://doi.org/10.1002/hep.28431.
2. Eslam M., Newsome P.N., Sarin S.K., et al A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020; 73 (1): 202–9. https://doi.org/10.1016/j.jhep.2020.03.039.
3. Buzzetti E., Pinzani M., Tsochatzis E.A. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016; 65 (8): 1038–48. https://doi.org/10.1016/j.metabol.2015.12.012.
4. Vilar-Gomez E., Martinez-Perez Y., Calzadilla-Bertot L., et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015; 149 (2): 367–78.e5. https://doi.org/10.1053/j.gastro.2015.04.005.
5. Zelber-Sagi S., Ratziu V., Oren R. Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence. World J Gastroenterol. 2011; 17 (29): 3377–89. https://doi.org/10.3748/wjg.v17.i29.3377.
6. Samala N., Tersey S.A., Chalasani N., et al. Molecular mechanisms of nonalcoholic fatty liver disease: potential role for 12-lipoxygenase. J Diabetes Complications. 2017; 31 (11): 1630–7. https://doi.org/10.1016/j.jdiacomp.2017.07.014.
7. Sanders F.W.B., Griffin J.L. De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose. Biol Rev Camb Philos Soc. 2016; 91 (2): 452–68. https://doi.org/10.1111/brv.12178.
8. Neuschwander-Tetri B.A. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology. 2010; 52 (2): 774–88. https://doi.org/10.1002/hep.23719.
9. Wree A., Broderick L., Canbay A., et al. From NAFLD to NASH to cirrhosisnew insights into disease mechanisms. Nat Rev Gastroenterol Hepatol. 2013; 10 (11): 627–36. https://doi.org/10.1038/nrgastro.2013.149.
10. Marra F., Svegliati-Baroni G. Lipotoxicity and the gut-liver axis in NASH pathogenesis. J Hepatol. 2018; 68 (2): 280–95. https://doi.org/10.1016/j.jhep.2017.11.014.
11. Chalasani N., Younossi Z., Lavine J.E., et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018; 67 (1): 328–57. https://doi.org/10.1002/hep.29367.
12. Bedogni G., Bellentani S., Miglioli L., et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006: 6: 33. https://doi.org/10.1186/1471-230X-6-33.
13. Eddowes P.J., Sasso M., Allison M., et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019; 156 (6): 1717–30. https://doi.org/10.1053/j.gastro.2019.01.042.
14. Wong V.W.S., Adams L.A., de Lédinghen V., et al. Noninvasive biomarkers in NAFLD and NASH – current progress and future promise. Nat Rev Gastroenterol Hepatol. 2018; 15 (8): 461–78. https://doi.org/10.1038/s41575-018-0014-9.
15. van der Windt D.J., Sud V., Zhang H., et al. The effects of physical exercise on fatty liver disease. Gene Expr. 2018; 18 (2): 89–101. https://doi.org/10.3727/105221617X15124844266408.
16. Hallsworth K., Adams L.A. Lifestyle modification in NAFLD/NASH: facts and figures. JHEP Rep. 2019; 1 (6): 468–79. https://doi.org/10.1016/j.jhepr.2019.10.008.
17. Hashida R., Kawaguchi T., Bekki M., et al. Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: a systematic review. J Hepatol. 2017; 66 (1): 142–52. https://doi.org/10.1016/j.jhep.2016.08.023.
18. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016; 64 (6): 1388–402. https://doi.org/10.1016/j.jhep.2015.11.004.
19. Loschi T.M., Baccan M.D.T.A., Della Guardia B., et al. Exercise training as an intervention for frailty in cirrhotic patients on the liver transplant waiting list: a systematic review. World J Hepatol. 2023; 15 (10): 1153–63. https://doi.org/10.4254/wjh.v15.i10.1153.
20. Sabag A., Barr L., Armour M., et al. The effect of high-intensity interval training vs moderate-intensity continuous training on liver fat: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2022; 107 (3): 862–81. https://doi.org/10.1210/clinem/dgab795.
21. Keating S.E., Hackett D.A., George J., Johnson N.A. Exercise and non-alcoholic fatty liver disease: a systematic review and metaanalysis. J Hepatol. 2012; 57 (1): 157–66. https://doi.org/10.1016/j.jhep.2012.02.023.
Review
For citations:
Zolozova E.A., Bogacheva T.E., Demidov V.I. Therapeutic exercise in non-alcoholic fatty liver disease: current approaches and evidence-based effectiveness. Journal of Medical Rehabilitation. 2025;3(3):193-199. (In Russ.) https://doi.org/10.17749/2949-5873/rehabil.2025.58
Views:
40
JATS XML
Email this article 